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Abstract: Worldwide, hepatitis C virus (HCV) is a common infection. Due to new 
antiviral approaches and the approval of direct-acting antiviral agents (DAA), HCV therapy 
has become more comfortable. Nevertheless, there are special patient groups, in whom 
treatment of HCV is still challenging. Due to only few data available, tolerability and efficacy 
of DAAs in special patient cohorts still remain unclear. Such special patient cohorts comprise 
HCV in patients with decompensated liver disease (Child-Pugh Class B or C), patients with 
chronic kidney disease, and patients on waiting lists to renal/liver transplantation or those with 
HCV recurrence after liver transplantation. HCV infection in these patient cohorts has been 
shown to be associated with increased morbidity and mortality and may lead to reduced graft 
survival after transplantation. Successful eradication of HCV results in a better outcome 
concerning liver-related complications and in a better clinical outcome of these patients.  
In this review, we analyze available data and results from recently published literature and 
provide an overview of current recommendations of HCV-therapy regimen in these special 
patient cohorts. 
Keywords: HCV infection; chronic kidney disease; renal transplantation; decompensated 
liver cirrhosis; liver transplantation; new therapy regimen; DAA treatment 
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1. Introduction 
Hepatitis C virus (HCV) infections are common worldwide. It is estimated that about 3% of  
the world’s population is infected by HCV, which results in 130–150 million carriers worldwide. 
According to the World Health Organization (WHO), 350,000 to 500,000 deaths per year are  
attributed to liver diseases caused by HCV. A sustained virological response (SVR) of HCV improves  
survival rates of HCV infected patients and lowers complication rates of HCV related liver disease.  
At the “American Association for the Study of Liver Diseases” (AASLD) meeting in November 2014, 
Hill and co-authors presented five-year observational data of 34,563 patients with and without SVR  
who had been treated with antivirals. The authors revealed that elimination of HCV resulted  
in a decrease of five-year-mortality of 62%–84%. According to their study, the risk for development of 
hepatocellular cancer (HCC) was lowered by 68%–79%; the risk for liver transplantation was strongly 
reduced and was lowered by 90% [1]. 
The launch of interferon-free regimens for the treatment of hepatitis c revolutionizes management  
of patients suffering from chronic hepatitis C infection. Response rates of more than 90%, improved 
tolerability and fewer side effects of the new drugs allow the treatment of patients who are contraindicated 
to interferon and who showed low response rates in interferon-based antiviral therapies. However, until 
now, few data are available exploring the tolerability and efficacy of direct-acting antiviral agents (DAA) 
in special patient cohorts. These include patients with decompensated liver disease (Child-Pugh Class B 
or C) or patients with HCV recurrence after liver transplantation. Moreover, advanced liver disease is 
commonly associated with advanced renal disease. High prevalence of HCV infection in patients with 
chronic kidney disease has been associated with increased morbidity and mortality in these patients. 
Therefore, HCV screening of patients suffering from chronic kidney disease before starting hemodialysis 
or consideration for transplantation is recommended. 
Until now, only few data are available concerning the efficacy and safety of the new DAAs in special 
patient cohorts. Therefore, new studies and so-called “real-life”-experience reports from hepatitis 
registries are required to clarify safety and efficacy in special patient cohorts such as kidney and/or liver 
transplant recipients, patients suffering from end-stage renal disease, or liver cirrhosis. 
In this review, we will explore these special patient cohorts and examine the current state of knowledge 
in this field. To establish further understanding, a comprehensive summary of pharmacokinetics of all  
the new DAAs in the setting of hepatic and renal impairment is added (Table 1). 
1.1. Data Sources 
A literature search was performed by looking for the search terms hepatitis C, HCV, renal insufficiency, 
renal impairment, chronic kidney disease, liver cirrhosis, end stage liver disease and liver transplantation. 
Only English studies from 1995 through 2015 were considered. In addition, further references and 
studies presented at the American Association for the Study of Liver Disease (AASLD) and the European 
Association for the Study of the Liver (EASL) congress as well from trials registered in clinicaltrials.gov 
were considered. 
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Table 1. Pharmacokinetics of direct-acting antiviral agents in hepatitis C treatment. 
Antiviral 
Agent 
Mechanism Dosage Absorption Cmax Metabolism Elimination 
Hepatic 
Impairment 
Renal Impairment 
Protein 
Bound 
t½ (h) Enzymes Involed in Metabolism 
Simeprevir 
NS3/4A 
protease 
inhibitor 
150 mg oral 
daily with 
food 
Bioavailability 
60% with food, 
take with food. 
After 
4–6 h 
Hepatic; saturable 
first pass 
metabolism 
Biliary 
excretion; 91% 
Renal < 1% 
Use in 
decompensated 
liver cirrhosis or 
moderate to  
severe hepatic 
impairment is not 
recommended. 
In patients with mild, 
moderate or severe renal 
impairment no dose 
adjustment is required.  
Data missing exploring  
the safety in end-stage renal 
disease and hemodialysis. 
>99% 
110–130 in 
healthy 
volunteers; 
41 in  
HCV-infected 
patients 
Simeprevir is metabolized via CYP2A4 
enzymes. Therefore, comedication with 
strong inducers or inhibitors of this 
enzyme is not recommended. Simeprevir 
is a mild inhibitor of CYP1A2 and 
intestinal CYP3A4. No effect on CYP2C9 
and 2C19 and 2D6 are documented. 
Sofosbuvir 
NS5B 
nucleotide 
HCV RNA 
polymerase 
inihibitor 
400 mg  
oral daily 
Bio-availability 
not determined. 
Take with or 
without food. 
After 
1 h 
Hepatic prodrug 
hydrolyzed to 
active metabolite 
GS-461203; 
dephosphorylated 
to predominant 
metabolite  
GS-331007 
Urine 80% 
(3.5% SOF, 
78%  
GS-331007) 
feces, 14% 
Hepatic 
impairment and 
liver cirrhosis do 
not have an effect 
on the AUC of 
Sofosbuvir and its 
metabolite. 
No dose adjustments are 
required for mild or 
moderate renal impairment 
(CrCl > 30 mL/min)  
(but safety and efficacy have 
not been established in 
patients with severe  
renal impairment  
(CrCl < 30 mL/min) or 
ESRD requiring 
hemodialysis. 
61%–65% 
Parent drug: 
0.4–0.75 
major 
circulating 
metabolite,  
GS-331007: 
27 
The metabolism is CYP450  
enzyme independent. 
Ledipasvir 
NS5A 
inhibitor 
90 mg  
oral daily 
Bio-availability 
32%–53%; 
solubility is  
pH-depentend, 
take with or 
without food. 
After 
4–6 h 
Hepatic, minimal; 
not CYP450 
mediated 
Feces 70%; 
Urine < 1% 
No dose 
adjustment is 
required in hepatic 
impaired patients. 
In patients with renal 
impairment no dose 
adjustment is required.  
but safety and efficacy have 
not been established in 
patients with ESRD 
requiring hemodialysis. 
>99.8% 50 
The metabolism is CYP450  
enzyme independent. 
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Table 1. Cont. 
Antiviral 
Agent 
Mechanism Dosage Absorption Cmax Metabolism Elimination 
Hepatic 
Impairment 
Renal Impairment 
Protein 
Bound 
t½ (h) Enzymes Involed in Metabolism 
Daclatasvir 
NS5A 
replication 
Complex 
inhibitor 
60 mg  
oral daily 
Bio-availability 
not determined. 
Take with or 
without food. 
After 
1–2 h 
Hepatic 
Feces, 88%; 
Urine, 7% 
No dose 
adjustment is 
Required in 
hepatic impaired 
patients. 
No dose adjustment  
is required in renal  
impaired patients. 
95.6% 12–15 
Daclatasvir is substrate for CYP3A4 and 
P-gp. Therefore, comedication including 
CYP3A4 and P-gp inducers is 
contraindicated. Daclatasvir is  
a moderate inhibitor of P-gp, BCRP  
and OATP1B1/3 and shows limited 
inhibitory effects on CYP3A4. 
(Paritaprevir/
Ritonavir/ 
Ombitasvir/
Dasabuvir) 
NS3/4A 
HCV 
protease 
inhibitor/ 
HIV protease 
inhibitor/ 
NS5A 
inhibitor + 
non-
nucleoside 
HCV 
polymerase 
inihibitor 
2 tablets of 
75 mg/50 mg/ 
12.5 mg  
oral daily + 
250 mg  
twice daily 
Bio-
Availability, 
70% for 
Dasabuvir, not 
determeined for 
other agents, 
take with food. 
After 
4–5 h 
Hepatic Feces > 86% 
In mild hepatic 
impairment  
(Child Pugh A) no 
dose adjustment  
is required.  
In moderate 
impairment (Child 
Pugh B) it is not 
recommended, in 
Child Pugh C it is 
contraindicated. 
No dose adjustment is 
required in renal impaired 
patients. The regimen has 
not been adequately  
studied in ESRD and  
hemodialysis patients. 
Dasabuvir > 
99.5%, 
Ombitasvir 
99.9%, 
Paritaprevir 
97%–98%, 
RTV > 99% 
5.5/4/23 + 6 
Paritaprevir inhibits OAT1Ba transporters 
and is metabolized via CYP3A4. Ritonavir 
inhibits CYP3A4. In combination it is 
used as a booster for concentrations of 
Paritaprevir. Ritonavir is a substrate, 
inhibitor and inducer of many enzymes 
and proteins. Dasabuvir is metabolized  
via CYP2C8 and CYP3A4. Ombitasvir  
is metabolized via hydrolysis and  
oxidation reactions. 
Drug information based on summary of product information and according to Burgess S et al. [2]. 
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1.2. Pharmacokinetics of Newly Available DAAs 
Table 1 briefly summarizes the pharmacokinetics of the new DAAS and provides clinicians with a 
brief understanding for potential pittfalls of DAA use in special patient cohorts of end-stage renal 
disease, decompensated liver cirrhosis and transplant medicine. For a more detailed overview of 
pharmacokinetics we refer to Burgess et al [2]. 
1.3. HCV Infection in Patients with Chronic Kidney Disease Stage 4 or 5 Including Candidates for 
Renal Transplantation 
Based on epidemiological studies, chronic HCV infection is known as an independent risk factor for 
the development of chronic kidney injury compared with patients without HCV [3,4]. Chronic HCV 
infection is associated with histological–pathological lesions in both native and transplanted kidneys. 
The relationship between positive HCV serology and chronic kidney injury is discussed, but considered 
controversial, in the literature. Immunological and non-immunological mechanisms leading to 
chronic kidney injury in HCV infected patients are discussed in the literature. The most common  
HCV-associated nephropathy is type 1 membrano-proliferative glomerulonephritis. Another 
manifestation is type II mixed cryoglobulinemia, which is related to HCV-containing immune complex 
deposition in the glomeruli. Other studies postulate that infection with HCV per se is associated with  
an increased risk for the development of renal insufficiency or proteinuria. Some connect proteinuria to  
be caused by a metabolic syndrome, which shows a higher prevalence in HCV-infected patients than in  
the general population. Another hypothesis postulates that chronic renal insufficiency in HCV infected 
patients could be the result of accelerated atherosclerosis promoted by HCV [5,6]. However, the 
mechanisms leading to chronic kidney disease in chronically HCV-infected patients are still unclear. 
Nevertheless, chronic HCV infection worldwide occurs in 20%–25% of patients suffering from chronic 
kidney disease. Furthermore, HCV infection is also associated with an increased morbidity and mortality in 
kidney transplant recipients [7–9]. According to several studies, 10%–25% of candidates considered for 
kidney transplantation concurrently suffer from advanced liver fibrosis or cirrhosis [10,11]. Moreover, 
kidney transplanted patients with HCV infection show higher rates of liver related complications and 
lower survival rates after transplantation than HCV-negative patients [7,12–14]. According to literature, 
8%–28% of kidney transplant recipients die due to chronic liver diseases [15]. In patients with chronic 
kidney injury, specific treatment of HCV prior to kidney transplantation results in a better graft  
function and improved survival rates after transplantation [12]. According to a risk analysis, an active 
HCV-replication at the time of transplantation was identified to be an independent risk factor for  
a subsequent kidney graft failure [16]. Consequently, HCV treatment before kidney transplantation  
may avoid abovementioned complications, thus Patients considered for kidney transplantation should  
be prioritized for treatment. 
Historically, PEG-interferon based treatment regimen was associated with low virological response 
rates in patients with end-stage kidney disease. Moreover, antiviral treatment including PEG-interferon 
after kidney transplantation is relatively contraindicated due to higher graft rejection rates [17,18]. 
Approval of new DAAs is highly promising for effective future treatment in these patients. However, 
until now, there are only few data exploring new antiviral treatment options in chronically kidney injured 
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patients (GFR < 30 mL/min or hemodialysis) and in kidney transplant recipients. The 3D combination 
(Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir) approved in January 2015 has been reviewed in phase 
II studies according to their pharmacokinetics and safety profile in patients with low-grade, moderate, 
and severe kidney injury. Results showed no clinical relevant modifications [19]. Preliminary results of 
an ongoing phase III study (ClinicalTrials.gov Identifier: NCT02207088) presented at the European 
Liver Congress (EASL) 2015 [20] seem to confirm the efficacy and safety of the 3D combination  
(Tables 2 and 3). So far, 20 non-cirrhotic patients are currently included, 13 of them on dialysis. 
Patients are treated for 12 weeks with the 3D regimen Paritaprevir/Ritonavir/Ombitasvir plus 
Dasabuvir. Patients with GT1a additionally receive 200 mg of ribavirin each, four hours before dialysis. 
All 20 patients are currently HCV-PCR negative and 10 patients have achieved sustained virological 
response (SVR) rates at Week 4 after stopping treatment. Furthermore, the compatibility of the 
medication is good. In eight patients, ribavirin had to be interrupted. Four of the patients were given 
erythropoetin in the further course. Only in one patient the hemoglobin level dropped below <8 g/dL. 
Preliminary pharmacokinetic data show mean Ctrough values of DAAs with stage 4 and 5 chronic kidney 
disease comparable to those without renal impairment, suggesting a good safety profile. 
No final data are available investigating the treatment with the NSB5-polymerase-inhibitor Sofosbuvir 
(SOF) in patients with severe kidney injury or hemodialysis. Currently, there is an ongoing clinical phase 
IIb study (ClinicalTrials.gov Identifier: NCT01958281) examining the safety and effectiveness of the 
combined use of Sofosbuvir + Ribavirin (RBV) in HCV genotypes 1 and 3 patients with end stage kidney 
injury (Table 3). First results show comparable Sofosbuvir levels and four-times higher plasma levels of 
its metabolite GS-331007 in comparison to HCV patients without kidney injury. No therapy limiting 
severe side effects were observed [21]. However, the lower dose of Sofosbuvir (200 mg per day) and 
ribavirin (200 mg per day) in a 24-week course might result in low SVR rates of 40% (4 patients out of 
10) in preliminary analysis. 
Furthermore, not yet released Grazoprevir in combination with Elbasvir has been evaluated in  
a phase-3 study [22] with HCV genotype 1 infected patients (Table 3). Seventy-six percent of patients 
were on hemodialysis and 19% had an eGFR of 15–29 mL/min. SVR12 rates of 116 patients are 
available. Patients received 12 weeks Grazoprevir and Elbasvir. Six out of 122 patients were withdrawn 
from the study for various non-therapy-associated reasons. Only one patient out of 116 patients that  
were treated for 12-weeks, suffered a relapse (SVR12 99%) (Table 2). Furthermore, the therapy was  
well tolerated with a reporting of serious adverse events in 14% of cases, thus holding potential for  
a further treatment option in HCV genotype 1 infected patients with chronic kidney disease. 
Table 2. SVR4 and SVR12 rates of HCV treatment in CKD stages 4/5 according to  
Saxena Varun et al. and Roth David et al. [22,23]. * Preliminary data. 
Study HCV Genotype Treatment Patients (n) SVR4 SVR12 
RUBY-I * GT 1b and 1a 
Paritaprevir/ritonavir + 
Ombitasvir + Dasabuvir (plus 
Ribavirin in GT 1a) for 12 weeks 
10 100% (10/10) 
100% 
(2/2) 
C-Surfer GT 1 Grazoprevir + Elbasvir for  12 weeks 116  
99% 
(15/116)
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However, outcomes of clinically conducted phase-II or -III studies often fail to match those observed 
in heterogenous “real-life” populations. Therefore, results of longitudinal observational HCV-studies or 
registries are very important to bridge the knowledge gap between investigation and “real-life” application. 
In comparison, “real-life” data from the longitudinal cohort study TARGET [23], reporting on 19 patients 
with severe kidney disease (stages 4/5) receiving either the combination of Sofosbuvir and Simeprevir 
(SMV) or the combination of Sofosbuvir plus Ribavirin or Sofosbuvir/Pegylated-Interferon and RBV, 
suggest high cure rates of 85% at the cost of more side effects, such as anemia, renal function deterioration 
and severe adverse events. 
Table 3. Inclusion and exclusion criteria of revised clinical studies in patients with advanced 
renal impairment. 
Study Inclusion Criteria Exclusion Criteria HCV GT Patients (n) Therapy 
RUBY-1 
- Treatment-naive adults 
- Clinically significant 
comorbidity 
GT 1 20 # 
3D regimen  
for 12 weeks 
(+RBV in  
GT 1a) 
- Chronic kidney disease with eGFR  
<30 mL/min/1.73 m2 
- HBV and HIV negative 
- Hemoglobin < 10 g/dL 
- Non-cirrhotic * 
NCT01958281 
- HBV or HIV negative - Prior null response to  
PEG + RBV 
GT 1 or 3 10 # 
SOF + RBV for 
24 weeks 
- Cirrhosis determination at screening 
- Treatment-naive and experienced adults 
- Current or prior history of 
hepatic decompensation 
- Chronic kidney disease with  
eGFR <30 mL/min/1.73 m2 
- Not on hemodialysis 
- Clinically significant 
comorbidity 
C-Surfer 
- Treatment-naive or experienced adults 
- Current or prior history of 
hepatic decompensation 
GT 1 235 
Grazoprevir + 
Elbasvir for  
12 weeks 
- Chronic kidney disease with  
eGFR <30 mL/min/1.73 m2, including 
patients on hemodialysis 
- Compensated cirrhosis allowed § 
- Advanced liver cirrhosis 
- HBV and HIV negative 
Study oversight of revised clinical studies focusing on patients with advanced renal impairment. (* Histologic 
diagnosis (Metavir score ≤ 3; Ishak score ≤ 4), or Screening FibroScan < 14.6 kPa or APRI ≤ 2 or Fibro Test ≤ 0.72; 
# preliminary data; § Histologic diagnosis or Screening FibroScan or Fibro Test). 
2. HCV Infection in Patients after Renal Transplantation with GFR >30 mL/min 
According to actual guidelines, kidney transplant recipients with renal function GFR >30 mL/min can  
be treated similar to patients with chronic HCV without any kidney injury. However, in patients after  
organ transplantation drug interactions with immunosuppressive agents have to be taken into account. 
Sofosbuvir, Daclatasvir (DAC) and Ledipasvir (LDV) show no or only minor effects on hepatic CYP3A4 
enzymes [31,32]. Therefore, dose adjustment of common immunosuppressive agents like cyclosporine 
and tacrolimus is usually not required. However, serum levels of immunosuppressive agents need to  
be closely monitored during antiviral treatment. In case of combined use of Ritonavir-bossted protease 
inhibitor Paritaprevir, dose adjustment of tacrolimus and cyclosporine is required. Due to prolonged blood 
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serum level duration of tacrolimus (7-fold higher) and cyclosporine (3-fold higher) under 3D-therapy 
regimen, dose adjustment is required depending on tacrolimus or ciclosporin trough levels. 
3. Patients with Decompensated Liver Cirrhosis 
The main target of anti-viral therapy in patients on the waiting list for liver transplantation is to 
prevent a HCV recurrence and reinfection of the graft [33]. Moreover, the number of organ donations 
remains critical in most transplant regions. Cure of hepatitis C may even result into withdrawal of 
selected patients on the transplant waiting list due to significant improved liver function. Depending on 
genotype, the historical therapy regimen combining Ribavirin und PEG-interferon showed only low 
response rates of about 20% in patients with end-stage liver cirrhosis [33–35]. Additionally, in many of 
these patients, treatment had to be interrupted due to therapy-related side effects such as cytopenia, 
infections and decompensation of cirrhosis. Interferon based therapy was highly associated with 
temporarily decreased liver function, which resulted in liver failure once therapy was administered  
at advanced stages of liver cirrhosis, resulting in only few studies exploring PEG-interferon-based  
therapy regimen in patients with Child Pugh Score >8. Overall PEG-interferon-based treatment cannot 
be recommended in this patient cohort [36]. 
However, with the approval of the latest generation DAAs like Sofosbuvir, Simeprevir, Daclatasvir, 
Ledipasvir and the 3D combination Paritaprevir/Ritonavir, Ombitasvir + Dasabuvir potent drugs for  
HCV therapy are now available. Clinical studies report response rates of these substances of >90% [37]. 
Nevertheless, there are only few data available exploring HCV treatment in patients with decompensated 
cirrhosis (Child-Pugh Class (CPC) A with evidence of portal hypertension or Child-Pugh class B or C). 
In the following, we summarize recent knowledge and treatment recommendations for this patient cohort. 
Fourty-eight-week therapy using Ribavirin and Sofosbuvir in 50 cirrhotic patients with either portal 
hypertension (CPC A) or with decompensated cirrhosis (CPC B) was recently presented [24] (Table 4). 
HCV GT 1–4 were included. The overall SVR12 rate was 72% (33/46). SVR12 was 78% in CPC A and 
68% in CPC B. Interestingly, the study also observed improvements of serum albumin, the MELD score 
and a decrease of bilirubin. Furthermore, a decrease of ≥10% in the hepatic venous pressure gradient 
(HVPG) was observed in 38% of patients, a decrease in HVPG of ≥20% in 24% of patients. Treatment 
was generally well tolerated and resulted in only a few cases to premature discontinuation of therapy due 
to adverse events (n = 4). 
The effect of Sofosbuvir/Ledipasvir + Ribavirin and the combination of Sofosbuvir + Daclatasvir + 
Ribavirin have been investigated in the SOLAR-2 study [25] and the ALLY-1 study [26] (Table 4). Both 
studies included patients with advanced or decompensated cirrhosis. In the SOLAR-2 study [25] patients 
with HCV genotype 1 or 4 and CPC B or C were treated for 12 or 24 weeks. Preliminary results revealed 
high SVR rates of 85%–88%, irrespective of treatment duration in genotype 1, whereas longer treatment 
duration was superior (SVR rate of 86% vs. 57%) in genotype 4. The SOLAR-2 study could also show 
improvement of MELD- and Child-Pugh Score in patients treated with LDV/SOF + RBV suffering from 
decompensated cirrhosis and post-liver transplantation. However, the reporting of seven deaths, even 
though not considered as treatment related by the authors, raise the question of safety issues of DAAs in 
this special patient cohort since it may be difficult to differentiate between the natural course of disease 
or direct toxicity from DAA therapy being causative for death. 
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Table 4. Inclusion and exclusion criteria of revised clinical studies in patients with decompensated liver cirrhosis or post liver transplantation. 
Study Inclusion Criteria Exclusion Criteria HCV GT Patients (n) Therapy Saftey (%) 
NCT01687257 
[24] 
- Cirrhosis with  
Child-Pugh score < 10 - HIV or HBV co-infection 
GT 1–4 50 
SOF + RBV 
for 48 weeks 
- AEs: 94% 
- Esophageal or gastric varices on endoscopy 
- HVPG > 6 mmHg - AFP > 50 unless negative imaging 
for hepatic masses within the last  
6 months or during screening 
- Grade 3–4 AEs: 20% 
- BMI ≥ 18 kg/m2 
- Treatment-naive to all nucleotides/nucleoside 
treatments for chronic HCV infection 
- Refractory ascites as defined by 
requiring paracentesis > twice within 
1 month prior to screening 
- Serious AEs: 22% 
- eGFR > 50 mL/min/1.73 m 
- No history of hepatorenal or  
hepatopulmonal syndrome 
- Active variceal bleeding within  
6 months of screening 
- Treatment D/C due to AE: 9% 
- Death: 0% 
SOLAR-2 
[25] 
- Treatment-naive or experienced adults 
- HBV or HIV co-infection 
GT 1 or 4 329 
SOF + LDV 
+ RBV for 12 
or 24 weeks 
- AEs: 94% 
- No hepatocellular carcinoma (HCC) 
- Grade 3–4 AEs: 25% 
- eGFR > 40 mL/min/1.73 m 
- eGFR > 40 mL/min/1.73 m 
- Previous treatment with DAA 
- Serious AEs: 28% 
- Platelets > 30,000/mL 
- Treatment D/C due to AE: 3% 
- CPC B or C cirrhosis 
- Or post LTx recurrence - Death: 4% 
ALLY-1 [26] 
- Treatment-naive or experienced adults - HIV or HBV co-infection as 
documented by HBV 
All GTs 113 
SOF + DCV 
+ RBV for  
12 weeks 
- AEs: 94% 
- Advanced cirrhosis * - Grade 3–4 AEs: 15% 
- Post-transplant subjects at least 3 months  
post-transplant with no evidence of moderate 
or severe rejection 
- Active hospitalization for 
decompensated liver disease 
- Serious AEs: 13% 
- Treatment D/C due to AE: 2% 
- Previous treatment with DAA - Death: 0% 
IMPACT [27] 
- Treatment-naive or experienced adults 
- Previous treatment with DAA 
GT 1 or 4 28 
SOF + DCV 
+ SMV 
- AEs: 67% 
- CPC A cirrhosis # with evidence of portal 
hypertension (esophageal varices or  
HPVG ≥ 10 mmHg 
- Grade 3–4 AEs: 0% 
- HBV or HIV co-infection 
- Serious AEs: 0% 
- Treatment D/C due to AE: 0% 
- CPC B cirrhosis # - Death: 0% 
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Table 4. Cont. 
Study Inclusion Criteria Exclusion Criteria HCV GT Patients (n) Therapy Saftey (%) 
CORAL-I [28] 
- Post liver transplant - HBV or HIV co-infection 
GT 1 34 
3D-regimen + 
RBV for  
24 weeks 
- AEs: 97% 
- Treatment-naive or experienced adults either 
pre or post liver or renal transplant 
- Use of everolimus or sirolimus as 
part of immunosuppressive regimen 
- Grade 3–4 AEs: 0% 
- Serious AEs: 6% - Currently taking an immunosuppressant 
regimen based on either tacrolimus or 
cyclosporine. Corticosteroids such as 
prednisone or prednisolone are permitted as 
components of the immunosuppressant regimen 
providing the dose is not more than 10 mg/day 
- No severe fibrosis or cirrhosis 
(Metavir score ≤ F2) - Treatment D/C due to AE: 3% 
- Death: 0% 
NCT01938430 
[29] 
- Post liver transplant 
- HBV or HIV co-infection 
GT 1 or 4 223 
SOF/LDV + 
RBV for 12 or 
24 weeks 
- AEs: 98% 
- Metavir F0–F3 
- Serious AEs: 20% 
- CPC A cirrhosis * 
- Total bilirubin ≤ 10 mg/dL,  
Hemoglobin ≥ 10 g/dL 
- Previous treatment with DAA 
- Treatment D/C due to AE: 3% 
- eGFR > 40 mL/min/1.73 m 
- Death: 2% 
- Platelets > 30,000/mL 
SATURN [30]  
- Post liver transplant 
- HBV or HIV co-infection 
GT 1b 35 
SMV + DCV 
+ RBV for  
24 weeks 
- AEs: 94% 
- Treatment-naive or experienced adults - Grade 3–4 AEs: 26% 
- Stable immunosuppressant regimen with either 
tacrolimus or ciclosporin - Evidence of acute or chronic hepatic 
decompensation after LTx 
- Serious AEs: 20% 
- Metavir-Score F1–F4 
- Treatment D/C due to AE: 6% 
- Death: 0% 
Study oversight of revised clinical studies focusing on patients with decompensated liver cirrhosis or pos liver transplantation. (* FibroScan with kPa >12 or FibroTest score 
of >0.75 and APRI > 2 or liver biopsy documenting cirrhosis; # FibroScan with kPa >14.5). 
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The ALLY-1 phase-III study [26] (Table 4) included patients with cirrhosis (n = 60) and HCV GT  
1-4. Patients were treated with the combination of Daclatasvir, Sofosbuvir and Ribavirin. Depending on 
Child-Pugh Class A-C SVR12 rates of 92%, 94% and 56% were achieved, respectively. Overall SVR12 
rates by HCV GT irrespective of CPC showed best results in GT 1b of 100%, 76% in GT 1a; 80% in GT 2, 
83% in GT 3 and 100% in GT 4, respectively. 
The findings demonstrate that this combination yields high SVR rates in cirrhotic patients irrespective 
of the GT but that further studies are required to define the best therapy management for Child-Pugh C 
patients. Moreover, a serum albumin level <2.8 g/dL was also associated with a poor SVR12 rate of 
56%, thus serving as a negative predictor. The treatment was overall well tolerated as summarized  
in Table 4. 
A related real-world National Health Service England (NHS E) funded observational study [38] 
investigated the efficacy of SOF combined with either LDV or DAC in mainly HCV GT 1 (235 patients) 
or GT 3 (189 patients) infected patients with decompensated liver cirrhosis (Child-Pugh Score > 7). 
Patients were treatment-naïve or experienced (Peg-IFN + RBV). The SVR12 rates by genotype and 
therapy regimen are shown in Figure 1. SOF/LDV with or without RBV, and SOF/DAC with RBV, did 
not work as well against GT 3 as they did against GT 1. However, SOF/DAC worked better for GT 3 
and addition of RBV had no beneficial effect. Moreover, over 40% of patients showed improvement in 
liver function by means of improvement of >2 MELD score points. The rate of serious adverse events 
of 26% was similar in comparison to abovementioned clinical trials. 
 
Figure 1. Adapted from Foster GR et al. [38]: Intention to treat analysis with SVR12 by 
genotype and therapy regime. 
Interim analysis of a French multicenter compassionate use program of Daclatasvir plus Sofosbuvir 
with or without ribavirin in liver cirrhosis and HCV GT 3 report SVR4 rates of 76% (22/29 patients) in 
a 12 weeks therapy regimen vs. 88% (52/54 patients) in a 24 weeks regimens [39]. Unfortunately, subgroup 
analyses of Child-Pugh status in this patient cohort are not available yet, limiting treatment recommendation. 
The ongoing IMPACT study (Phase-II) [27] (Table 4) analyses a 12-week treatment of the 
combination of Sofosbuvir, Daclatasvir and Simeprevir in patients with HCV GT 1 or 4 and decompensated 
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liver cirrhosis. So far, 28 patients with CPC B or CPC A with evidence of portal hypertension have been 
evaluated. All patients with available data have achieved SVR4 (CPC A 12/12; CPC B 2/2). Tolerability 
of the treatment was good. Moreover, pharmacokinetic analysis revealed SMV exposures in CPC B 
patients to be within the range observed for CPC A patients, thus, in contrast to the label of SMV, 
suggesting possible use in decompensated cirrhosis. 
As for the 3D regimen (Paritaprevir/Ritonavir + Ombitasvir + Dasabuvir ± Ribavirin), no data on 
treatment in HCV GT 1 with decompensated cirrhosis are available yet. However, an integrated analysis 
of six phase-III trials of GT 1 patients receiving Ombitasvir/Paritaprevir/r, Dasabuvir with or without 
Ribavirin (RBV) for 12 and 24 weeks have shown excellent SVR12 rates in compensated cirrhosis 
(Child-Pugh Score < 6) of 96% (n = 189 patients) [40]. As results from a post-hoc analysis of 
TURQUOISE-II [41], which did not include cirrhotic patients, implicate an improvement in total 
bilirubin levels, α-fetoprotein levels (AFP), international normalized ratio (INR), absolute platelet count 
and serum albumin levels after a 12 to 24 week treatment with the 3D regimen, an improvement in liver 
function might also be assumed for the special patient cohort of patients with advanced cirrhosis.  
To what extent these results are applicable to patients with advanced cirrhosis is currently evaluated in 
the TURQUOISE-CPB study (ClinicalTrials.gov Identifier: NCT02219477). 
However, outcomes of clinically conducted phase-II or -III studies often fail to match those observed 
in heterogenous “real-life” populations. Therefore, results of longitudinal observational HCV-studies or 
registries are very important to bridge the knowledge gap between investigation and “real-life” application. 
Interim results from the longitudinal, observational HCV-TARGET study [42] have included a total 
of 256 patients (n = 183 HCV GT1; n = 30 HCV GT2; n = 33 HCV GT3) with liver cirrhosis (n = 219 Model 
of Endstage Liver Disease (MELD) Score 10–15; n = 29 MELD Score 16–21; n = 10 MELD Score > 21)  
so far. SVR12 rates of 216 patients are available at date. Patients have either received a combination of 
SOF + RBV (n = 76), SOF + SMV (n = 108) or the combination of SOF + SMV plus RBV (n = 32). Overall 
SVR12 rates depending on the genotype or MELD Score are demonstrated in Figure 2. 
 
(a) 
Figure 2. Cont. 
Int. J. Mol. Sci. 2015, 16 18045 
 
 
(b) 
Figure 2. Adapted from Reddy et al. [42]: SVR12 by Genotype (a); and MELD Score (b) 
depending on treatment regimen. 
Moreover, the authors documented an improvement of bilirubin and albumin levels in 80% and  
61% of patients, respectively. Twenty-six of their patients had baseline MELD and post treatment  
data available. Of them, 18 had improvement, five unchanged, and three worsened after four weeks  
of treatment. The authors showed that markers of hepatic and synthetic function improved during  
the short-term follow-up. 
Furthermore, final evaluation of 954 “real-life” HCV patients treated with 12 weeks regimens 
containing SOF ± SMV in the TRIO Health program have recently been presented at EASL 2015 [43]. 
290 patients with cirrhosis were included, receiving either 12 weeks of Peg-Interferon + RBV + SOF, 
RBV + SOF or SMV + SOF ± RBV. Table 5 overviews the SVR12 rates. Subgroup analysis of cirrhosis 
stage and its correlation with SVR rates unfortunately have not been published yet. 
Table 5. Per protocol analysis of SVR12 rates in the TRIO Health Program. 
Genotype PEG + RBV + SOF SMV + SOF ± RBV SOF + RBV 
GT1 77% (n = 54/70) 83% (n = 110/133) n.a. 
GT2 n.a. n.a. 93% (n = 140/150) 
Adapted from Dieterich et al. [43]: Per protocol analysis of SVR12 rates in HCV GT1 or GT2 infected  
patients with liver cirrhosis treated with 12 weeks regimens containing Sofosbuvir ± Simeprevir in the TRIO  
Health program. 
As for now, according to the results of the abovementioned studies and currently available EASL and 
AASLD recommendations but also in awareness of yet limited available data we suggest following 
therapy regimens in patients with decompensated liver cirrhosis: (Table 6). 
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Table 6. Treatment recommendations for patients with decompensated liver cirrhosis. 
HCV Genotype Therapy 
GT 1 
• Ledipasvir + Sofosbuvir + Ribavirin for 12 weeks. In case of Ribavirin 
intolerance treatment prolongation up to 24 weeks should be evaluated. 
• Simeprevir + Sofosbuvir for 12 weeks. 
GT 2 • Sofosbuvir + Ribavirin for up to 48 weeks. 
GT 3 • Sofosbuvir + Daclatasvir + Ribavirin for 24 weeks. 
GT 4 • Ledipasvir + Sofosbuvir + Ribavirin for 24 weeks. 
GT 5/6 • No data available. 
Recommendations for patients with decompensated liver cirrhosis. Since drug approval of the DAA’s vary, 
health care cost recovery should be evaluated prior to treatment start. Recommendations are given for DAA 
combinations with most data available at the moment. 
4. Patients with HCV-Recurrence after Liver Transplantation 
HCV related liver cirrhosis with or without HCC is the foremost indication for liver transplantation 
within the UNOS regions and Eurotransplant [44]. HCV recurrence in patients with detectable  
HCV-RNA at the time of transplantation is somewhat of 100%. In patients who do not receive antiviral 
treatment, liver cirrhosis occurs in up to 25% within five years of liver transplantation and long-term survival 
is reduced by 25% compared to patients with other diagnosis leading to liver transplantation [45,46]. 
Therefore, HCV infection in liver transplant recipients should be close monitored and treated. Up to 
now, the standard therapy regimen combining Pegylated-Interferon and Ribavirin showed marginal 
response rates of 30%–40% [47–49] in this patient cohort. Furthermore, interferon-containing regimens 
also contain a higher risk of toxic effects in liver transplant recipients who receive immunosuppressive 
therapy that might lead to termination of antiviral therapy. Approval of new potent DAAs provides hope 
that sustainable HCV healing in liver transplant recipients may become feasible. Preliminary data from 
TARGET-cohort analyzing HCV treatment in liver transplant recipients with genotype 1 show SVR in 
90% of patients who received Sofosbuvir/Simeprevir with or without Ribavirin 4 weeks after finishing 
treatment (SVR4) [50]. The ongoing CORAL-1 (Table 4) study exploring HCV non-cirrhotic genotype 
1 liver transplant recipients treated with 3D-combination (Paritaprevir/Ritonavir, Ombitasvir and 
Dasabuvir) + Ribavirin for 24 weeks demonstrated SVR rates of 97% [28]. First data (NCT01938430) 
available for liver-transplant recipients receiving a combination of Sofosbuvir/Ledipasvir + Ribavirin 
(Table 4) also revealed excellent results. Therapy was well tolerated, even in patients with decompensated 
cirrhosis. Deaths occurred in 2% of cases but were not considered as therapy related. In patients with 
low-grade liver fibrosis (grade F0–F3) as well as in patients with compensated liver cirrhosis (Child-Pugh 
Class A), 12- and 24-weeks of therapy, respectively, led to response rates of 96%, whereas patients with 
Child B or C liver cirrhosis showed lower SVR rates of 85% and 65%, respectively [29]. The authors 
also documented that SVR12 in patients with decompensated cirrhosis is associated with improvements 
in CPC and MELD scores, indicating that HCV clearance can improve hepatic function by diminishing 
HCV-related liver inflammation. 
The ALLY-1 phase-III study [26] also included patients with HCV recurrence after liver transplantation 
(n = 53). Thirty precent of the patients also had a Metavir Score F4 at the time of inclusion. Patients with 
HCV GT 1–6 (77% GT1, 21% GT3, 2% GT6) were treated with Daclatasvir + Sofosbuvir + Ribavirin 
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for 12 weeks. Ninety-four percent of liver transplant recipients with HCV recurrence achieved SVR12. 
Moreover, due to a favorable drug-drug interaction profile no dose modification of immunosuppressant 
medication was necessary in this patient cohort, suggesting a high efficacy and safety of this treatment 
combination for this special patient cohort. 
Preliminary results of 35 patients in the on-going phase-II study SATURN [30] (Table 4), investigating 
the combination of SMV + DAC + RBV in patients with recurrent HCV GT 1b infection after liver 
transplantation, including non- and cirrhotic patients, are showing high SVR4 rates of 90%–93%, also 
demonstrating promising results in this patient cohort. Simeprevir should not be administered with 
cyclosporine. Safety and tolerability were reported to be good with only few grade 3–4 adverse events. 
Based on the currently available data, DAAs seem to be safe and effective in the treatment of liver 
transplant recipients. 
According to available data, we suggest starting Ledipasvir/Sofosbuvir ± Ribavirin therapy early in 
liver transplant patients with recurrence of HCV genotype 1 and 4 (Table 7). To date, there are no  
data available concerning the combined use of sirolimus and everolimus inhibitors and Ledipasvir. 
Additionally, no data for the interaction-potential for mycophenolate mofetil, mycophenolic acid, or 
azathioprine and Ledipasvir exist but it is expected that Ledipasvir and Sofosbuvir do not have 
interactions with these immunosuppressive agents. 
Table 7. Treatment recommendations for HCV recurrence after liver transplantation. 
HCV Genotype Therapy 
GT 1 
• Ledipasvir + Sofosbuvir + Ribavirin for 12 weeks. In case of Ribavirin 
intolerance treatment prolongation up to 24 weeks should be evaluated. 
• Simeprevir + Sofosbuvir ± Ribavirin for 12 weeks. 
• Paritaprevir, ritonavir, Ombitasvir and Dasabuvir with Ribavirin for 12 weeks  
(genotype 1b) or 24 weeks (genotype 1a with cirrhosis). 
GT 2 
• Sofosbuvir + Ribavirin for 12 weeks (also accounts for patients with  
post-transplant compensated cirrhosis). In decompensated cirrhosis 
prolongation up to 24 weeks should be evaluated. 
GT 3 
• Sofosbuvir + Daclatasvir + Ribavirin for 12–24 weeks depending on presence 
of post-transplant cirrhosis. 
GT 4 
• Ledipasvir + Sofosbuvir + Ribavirin for 24 weeks. 
• Paritaprevir, ritonavir and Ombitasvir plus Ribavirin for 12 or 24 weeks 
depending on presence of post-transplant cirrhosis. 
• Sofosbuvir + Simeprevir ± RBV for 12 weeks. 
GT 5/6 • No data available. 
Recommendations for patients with HCV recurrence after liver transplantation. Since drug approval of the 
DAAs vary, health care cost recovery should be evaluated prior to treatment start. Recommendations are given 
for DAA combinations with most data available at the moment. 
In genotype 1 and 4, the 3D regimen can also be administered leading to comparable response rates 
(Table 7). Special attention should be given to drug interactions caused by ritonavir. Therefore, levels 
of immunosuppressive agents (such as tacrolimus or cyclosporine) have to be monitored closely and 
dose adjustments should be considered during therapy with such a booster protease inhibitor. Based on 
the TARGET study [50] the combination of Simeprevir + Sofosbuvir ± Ribavirin leads to high SVR4 
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rates of 90% and thus can also be evaluated. In genotype 2 and 3, we suggest a primary regimen using 
the combination Sofosbuvir + Ribavirin for 24 weeks. In genotype 3 the combination of Sofosbuvir + 
Daclatasvir + Ribavirin for 12 weeks can be applied alternatively. 
Table 7 gives and overview of treatment recommendations for this special patient cohort. 
5. Conclusions 
According to the results of studies available to date, the use of DAAs in patients with CKD stages 
4/5, decompensated liver cirrhosis and in those with HCV recurrence after renal and liver transplantation 
seems reasonable. 
In liver transplant recipients who show reinfection, we suggest starting antiviral therapy early in the 
course. We recommend interaction checks for the administered medication especially a close monitoring 
of immunosuppressive agents and measurement of their blood levels to prevent toxicity or rejections. 
Moreover, based on the excellent response rates of HCV under new therapy regimen one should discuss 
new opportunities of recruiting liver organs in times of organ shortage. In case of considering HCV-positive 
organs for extended donor criteria waiting times could be reduced, e.g., in patients who are not 
sufficiently represented by the MELD score. Thus, risk of dying during the waiting time period might 
be reduced in these patients. 
Despite the lack of data concerning antiviral treatment in patients with chronic kidney disease,  
the EASL [37] has already taken up this issue suggesting antiviral treatment in chronic kidney disease, 
particularly those who are suitable candidates for renal transplantation. Until more data are available, 
antiviral treatment of HCV patients with GFR < 30 mL/min or hemodialysis should exclusively be performed 
in specialized centers. According to our experience, treatment is feasible in individual cases; however, 
plasma level monitoring may be a helpful tool to manage the treatment. Simeprevir, Daclatasvir and  
the 3D combination can be considered. Depending on cirrhosis status 12 or 24 week therapy regimens 
should be applied. Moreover, in case of Ribavirin administration, individualized dosing is recommended. 
For possible interactions with co-medication, we recommend www.hep-druginteractions.org,  
which provides an overview about possible interactions of DAAs and is being timely updated after new 
drug approvals. 
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